blood advances

American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
bloodadvances@hematology.org

T-replete cord transplants give superior outcomes in high risk and relapsed/refractory paediatric myeloid malignancy

Tracking no: ADV-2022-009253R1

Claire Horgan (Royal Manchester Children's Hospital, United Kingdom) Khushnuma Mullanfiroze (Great Ormond Street Hospital, United Kingdom) Archana Rauthan (Great Ormond Street Hospital, United Kingdom) Katharine Patrick (Sheffield Children's Hospital, United Kingdom) Naeem Butt (Bristol Royal Hospital for Children, United Kingdom) Oana Mirci-Danicar (Bristol Royal Hospital for Children, United Kingdom) Olya O'Connor (The Royal Marsden NHS Foundation Trust, United Kingdom) Caroline Furness (The Institute of Cancer Research, United Kingdom) Akshay Deshpande (Birmingham Children's Hospital, United Kingdom) Sarah Lawson (Birmingham Women's and Children's Hospitals, Birmingham, UK., United Kingdom) Valerie Broderick (CHI at Crumlin, Ireland) Pamela Evans (Children's Health at Crumlin, Ireland) Brenda Gibson (Royal Hospital for Children, United Kingdom) Wing Roberts (Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, United Kingdom) Salah Ali (Leeds Children's Hospital, United Kingdom) Sevasti Galani (CR UK & UCL Cancer Trials Centre, United Kingdom) Amy Kirkwood (UCL, United Kingdom) Jelena Jovanovic (King's College, United Kingdom) Richard Dillon (King's College, London, United Kingdom) Paul Virgo (North Bristol NHS Trust,) Beki James (Leeds Children's Hospital, United Kingdom) Kanchan Rao (Great Ormond Street hospital, United Kingdom) Persis Amrolia (Great Ormond St Children's Hospital, United Kingdom) Robert Wynn (Royal Manchester Children's Hospital, United Kingdom)

Abstract:
Stem cell transplant (SCT) outcomes in high-risk (HR) and relapsed/refractory (R/R) paediatric acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) have been poor historically. Cord blood allows T-cell replete transplant (TRCB), enabling enhanced graft-versus-leukaemia. We collected data from 367 consecutive patients undergoing TRCB (112 patients) or other cell source (255 patients) SCT for paediatric AML/MDS in the UK and Ireland between January 2014 and December 2021. Data was collected about patient's demographics, disease and its treatment including previous transplant, measurable residual disease (MRD) status at transplant, HLA-match, relapse, death, graft versus host disease (GvHD) and transplant-related mortality (TRM). Univariable and multivariable analyses were undertaken. There was a higher incidence of poor prognosis features in the TRCB cohort: 51.4% patients were MRD positive at transplant, 46.4% had refractory disease and 21.4% had relapsed after a previous SCT, compared with 26.1%, 8.6% and 5.1% respectively in the comparator group (all p <0.001). Within the TRCB cohort, Event Free Survival (EFS) was 64.1%, 50% in MRD positive patients and 79% in MRD negative (p= 0.009). To allow for the imbalance in baseline characteristics, a multivariable analysis was performed: the TRCB cohort had significantly improved EFS (0.57[0.35-0.91], p=0.019), time to relapse (0.46[0.26-0.81), p=0.008), and reduced chronic GVHD (HR 0.28 [95% CI 0.11-0.70]; p=0.007), with some evidence of improved Overall Survival (OS) (0.65[0.39-1.07], p = 0.088). The effect appeared similar regardless of MRD status, (interaction p-value= 0.29). CB transplant without serotherapy may be the optimal transplant option for children with myeloid malignancy.

Conflict of interest: No COI declared

COI notes:

Preprint server: No;

Author contributions and disclosures: RFW and PA conceived and designed study. RFW, PA, KR, OM-D, CF, BJ, KP, SL, BG, WR, PE approved the study through the UK Paediatric BMT cooperative network. KM, AR, KP, NB, OM-D, OO'C, CF, AD, VB, PE, BG, WR, SA, JJ, RD, PV collected and supplied all institutional data. CH and RFW wrote the manuscript. CH, SG and AK analysed data. SG and AK critically interpreted data and produced figures and tables. All authors reviewed, edited and approved the submitted manuscript.

Non-author contributions and disclosures: No;

Agreement to Share Publication-Related Data and Data Sharing Statement: emails to the corresponding author

Clinical trial registration information (if any):

T-REPLETE CORD TRANSPLANTS GIVE SUPERIOR OUTCOMES IN HIGH RISK AND RELAPSED/REFRACTORY PAEDIATRIC MYELOID MALIGNANCY

Cord blood transplant in paediatric AML/MDS

Authors

Claire Horgan[1], Khushnuma Mullanfiroze[2], Archana Rauthan[2], Katharine Patrick[3], Naeem Akram Butt[4], Oana Mirci-Danicar[4], Olya O'Connor[5], Caroline Furness[5,6], Akshay Deshpande[7], Sarah Lawson[7], Valerie Broderick[8], Pamela Evans[8], Brenda Gibson[9], Wing Roberts[10], Salah Ali[11], Sevasti Galani[12], Amy A Kirkwood[12], Jelena Jovanovic[13] Richard Dillon[13], Paul Virgo[14], Beki James[11], Kanchan Rao[2], Persis J Amrolia[2], Robert F Wynn[1]

[1]Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK
[2]Great Ormond Street Hospital for Children, Great Ormond Street, London, WC1N 3JH, UK
[3] Sheffield Children's NHS Foundation Trust, Clarkson Street, Broomhall, Sheffield, S10 2TH, UK
[4]Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, UK
[5]The Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ, UK
[6]The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK
[7]Birmingham Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK
[8]Children's Health Ireland at Crumlin, Cooley Road, Crumlin, Dublin, D12 N512, Ireland
[9]Royal Hospital for Children, 1345 Govan Road, Glasgow, G51 4TF, UK
[10]Great North Children's Hospital, Victoria Wing, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP UK
[11] Leeds Children's Hospital, Clarendon Wing, Leeds General Infirmary, Leeds, LS1 3EX, UK
[12]CR UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, 90 Tottenham Court Road, London, W1T 4TJ, UK
[13]Department of Medical and Molecular Genetics, King's College, Strand, London, WC2R 2LS, UK
[14] Department of Immunology and Immunogenetics, North Bristol NHS Trust, Southmead Road, Bristol, BS10 5NB, UK

Corresponding author:
Robert F Wynn
Email: Robert.wynn@mft.nhs.uk
Telephone: 0044 161 701 6892
Address: Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK

Submission demographics

- Abstract: 249 words
- Text: 3400
- Figures: 7
- Tables: 2 (found at end of manuscript document)
- References: 40

Key point summary

- Compared to other cell sources, T-replete cord transplant results in improved disease-free survival and relapse risk in paediatric AML/MDS
- Compared to other cell sources, cord transplant cures with less chronic GVHD and particularly improves GvHD-free, Relapse-free survival

Abstract

Stem cell transplant (SCT) outcomes in high-risk (HR) and relapsed/refractory (R/R) paediatric acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) have been poor historically. Cord blood allows T-cell replete cord blood transplant (TRCB), enabling enhanced graft-versus-leukaemia. We collected data from 367 consecutive patients undergoing TRCB (112 patients) or other cell source (255 patients) SCT for paediatric AML/MDS in the UK and Ireland between January 2014 and December 2021. Data was collected about patient's demographics, disease and its treatment including previous transplant, measurable residual disease (MRD) status at transplant, HLA-match, relapse, death, graft versus host disease (GvHD) and transplant-related mortality (TRM). Univariable and multivariable analyses were undertaken. There was a higher incidence of poor prognosis features in the TRCB cohort: 51.4% patients were MRD positive at transplant, 46.4% had refractory disease and 21.4% had relapsed after a previous SCT, compared with 26.1%, 8.6% and 5.1% respectively in the comparator group (all p <0.001). Within the TRCB cohort, Event Free Survival (EFS) was 64.1%, 50% in MRD positive patients and 79% in MRD negative (p= 0.009). To allow for the imbalance in baseline characteristics, a multivariable analysis was performed: the TRCB cohort had significantly improved EFS (0.57[0.35-0.91], p=0.019), time to relapse (0.46[0.26-0.81), p=0.008), and reduced chronic GVHD (HR 0.28 [95% CI 0.11-0.70]; p=0.007), with some evidence of improved Overall Survival (OS) (0.65[0.39-1.07], p = 0.088). The effect appeared similar regardless of MRD status, (interaction p-value= 0.29). CB transplant without serotherapy may be the optimal transplant option for children with myeloid malignancy.

Manuscript

Introduction

Allogeneic haematopoietic stem cell transplant (SCT) is the treatment of choice to cure high risk, relapsed and refractory acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) (1, 2, 3) . Patients transplanted in remission do better than those with refractory disease (4, 5, 6). This is true also for patients who relapse and are transplanted in second remission (1, 5, 7, 8), including those who relapse after transplant (9).

Relapse is prevented by a graft-versus-leukaemia (GVL) effect mediated by alloreactive donor T-cells directed at residual recipient haematopoiesis and leukaemia (10). The increased risk of relapse in patients treated with T-cell depleted grafts, the efficacy of donor lymphocyte infusions (DLI) post-transplant to achieve disease control and an inverse correlation between graft-versus-host disease (GVHD) and relapse (11) indicate this critical role of donor-derived T-cells.

Milano *et al* (12) reported reduced relapse rates (RR) in cord blood (CB) SCT recipients compared to other donor cell sources in a single institution study of adult patients with all types of acute leukaemia. This was particularly striking for patients who had positive measurable residual disease (MRD) before transplant, and in such patients, this reduced RR was associated with improved disease-free survival (DFS). In MRD negative patients the RR was still reduced compared to other cell sources, but this less clearly translated to an improved DFS because of the increased transplant related mortality (TRM) in CB recipients. In a large, retrospective registry study of Japanese adult patients with non-remission AML, RR was reduced in CB SCT recipients compared to matched family donors, and their DFS was better (13). The low incidence of chronic GVHD (14) combined with the GVL effect that CB affords has also resulted in superior chronic GVHD-free relapse-free survival (GFRFS) for CB compared to other donor sources in further studies (15, 16).

CB T-cells might mediate an augmented GVL since such transplant is more often performed T-cell replete and is more often HLA-mismatched, compared to other cell sources. There is therefore both more rapid T-cell reconstitution (17) and a greater difference between host and recipient. Indeed, more complete HLA-matching is associated with poorer DFS in adult leukaemia patients receiving a CB transplant (18, 19). The greater permissiveness for HLA disparity between donor and recipient with CB enhances the donor pool (20) and is associated with low rates of chronic GVHD (15, 16, 21). These reasons, along with the rapid availability of CB units, makes CB a particularly appealing donor source, especially for high-risk and relapsed or refractory malignancies where timely access to SCT is essential. In-vitro xenograft studies have also demonstrated an enhanced anti-leukaemia effect for CB compared to similarly HLA-mismatched adult T-cells, supporting the possibility that cord blood T-cells have an ontogeny difference to adult T-cells that may be beneficial in curing leukaemia (22).

We report the utility of T-replete CB transplant in high-risk paediatric myeloid malignancies in a large multi-centre national analysis, comparing it with patients transplanted with similar disease and in the same period using other donor sources. We assessed DFS, RR, TRM and GFRFS, and compared outcomes in those with and without detectable measurable residual disease (MRD) at the time of transplant.

Methods

Data were collected from consecutive patients undergoing T-replete (without serotherapy) cord blood transplant for paediatric AML or MDS in 10 UK and Republic of Ireland paediatric bone marrow transplant centres between January 2014 and December 2021. The comparator group consisted of consecutive paediatric patients undergoing either a T-cell depleted cord blood HSCT or a transplant using any other cell source at the same centres over the same period for the same indication. Information was gathered directly from the centre using an agreed data proforma, and checked for accuracy and completeness against the BSBMT/EBMT Med A data submissions of each centre. Patients were consented to provide data for outcomes analysis and information was gathered directly.

Data were collected about patient's demographics, disease and its treatment including previous transplant, MRD, disease status at transplant, donor and HLA-match, relapse, death, GVHD and TRM.

Flow MRD was determined by multiparameter/multidimensional flow cytometry using aberrant expression of surface antigens on leukemic blasts and considered positive if >0.1%. The methodology used for measuring flow MRD was the same in both T-replete and comparator cohort, and all samples were assessed at centralised laboratories. The pre-transplant MRD status was assessed after their most recent course of chemotherapy prior to starting transplant conditioning (within 4 weeks of transplant).

The patient's clinical disease status was clinician-determined, and patients were classified as having refractory disease if >5% blasts in bone marrow either morphologically or by cytogenetic or molecular methods, or proven extramedullary disease after ≥2 courses of induction or reinduction chemotherapy.

All cords were matched out of eight loci at HLA-A, HLA-B, HLA-C and HLA-DRB1 at allelic level. Related and unrelated donors were matched out of 10 HLA loci at allelic level which were HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1.

Acute GVHD was graded according to the Glucksberg criteria (23) and chronic GVHD according to the NIH consensus (24).

Descriptive statistics were used to summarise the transplant characteristics for the whole cohort. Differences between treatment groups were assessed with Chi-square test or Fisher's exact tests (discrete variables) and Wilcoxon rank sum tests (continuous variables). Event free survival (EFS) and overall survival (OS) were calculated using the Kaplan Meier survival analyses and groups were compared using Cox regression and the log rank test. Competing risks analysis by the method of Fine and Grey was used to calculate the hazard ratios for relapse, non-relapse mortality, chronic and acute GVHD with relapse, non-relapse mortality, chronic and acute GVHD considered as competing risks. All times were calculated from the date of transplant to the date of the events or competing risk. Patients without an event were censored at the date last seen.

Univariable Cox regression was used to examine the effect of treatment group and other transplant characteristics on each time to event outcome. Interactions between the treatment group and the other parameters were assessed. Univariable analyses were carried out for the whole cohort, within the group of patients undergoing T-replete cord transplant and within the groups of patients with positive and negative MRD. Multivariable Cox regression analyses were performed for the whole cohort and forward selection was used when the number of events precluded full Multivariable analyses (MVA). Analyses were performed by using Stata 17.0 (STATAcorp, Texas).

All patients consented to data collection, and all centres consented to the use of this data by BSBMT for data analysis.

Results

Data were collected from 112 consecutive patients undergoing TRCB (TRCB) transplantation and 255 consecutive patients in the comparator group (136 matched unrelated donor (MUD), 63 matched sibling donor (MSD), 36 mismatched unrelated donor (MMUD), nine T-deplete cord and 11 haplo-identical donor).

Table 1 shows transplant characteristics for the whole cohort. With the exception of disease type (AML/MDS), groups were unbalanced. Patients in the T-replete cord group were younger (median age 6.5 [IQR 2.5-11 years vs 8.9 [3.9-13.2], p<0.005) and less likely to have received a HLA-matched donor: 32 (28.6%) vs 208 (81.6%), p<0.001. More patients in the cord group received reduced intensity conditioning; 20 (17.9%) versus 22 (8.6%), p=0.011. Importantly, there was an excess of poor prognostic features in the TRCB group, including almost twice as many MRD positive patients; 57 (51.4%) versus 60 (26.1%), p<0.001, more refractory patients; 52 (46.4%) versus 22 (8.6%), p<0.001, and four times higher proportion of 2nd transplants in the TRCB group; 20 (21.4%) vs 13 (5.1%), p<0.001.

Twenty four patients in the TRCB group had received a previous transplant. The majority of these (18/24) were from matched unrelated donor transplants, with 3/24 mismatched unrelated donor transplants, 1 haplo-identical transplant and 2 T-deplete cords.

Although data were collected over the same time period, TRCB transplants were more common in later years (63% of the patients in the comparator vs 36% in the TRCB group were transplanted in 2014-2017) leading to shorter median follow-up; 54.2 months (47.8-58.3) in the comparator and 24.6 months (16.3-34.4) in the T-replete group, due to this imbalance all survival rates and cumulative incidences have been calculated at 2 years.

The overall survival (OS) of the TRCB cohort was 64.7% and the event-free survival (EFS) was 64.1%. The EFS in patients who were flow MRD negative prior to transplant was 79%, and 50% in those that were flow MRD positive at transplant (p= 0.009, HR 2.58 [95% CI: 1.27, 5.26]), figure 1. EFS stratified by clinical disease status was 60.9% for those with primary refractory disease, 44.8% in those with relapsed refractory disease, 67.6% for those in high risk CR1 and 79.6% for those in CR2, figure 2. For the 24 patients who had received a previous BMT, EFS was 69%. 67% TRCB recipients developed acute GVHD, 30% was grade 3-4 and 37% grade 1-2 but the cumulative incidence of chronic GVHD was very low at 5% (95% CI 0.02-0.11). HLA match did not influence EFS.

Univariable analyses showed that there was no significant difference in EFS by cell source groups (HR 1.04 [95% CI 0.72-1.52]; p=0.82) with 2-year EFS rates of 64.1% (53.3-73) for TRCB versus 60.3% (95% CI 53.8-66.21) for comparator group. Analyses of OS showed similar effects with no significant difference between the groups (HR 1.32 [95% CI 0.89-1.96]; p-value=0.17). TRCB was associated with significantly higher non-relapse mortality (HR 2.05 [95% CI 1.05-4.01]; p=0.04) with 2-year cumulative incidence of 12.3% (7.3-20.4)

for T-replete versus 7.2% (95% CI 4.6-11.2) for comparator group, Figure 3. Despite this, TRCB group were at significantly lower risk of developing chronic GVHD, (HR 0.25 [95% CI 0.10-0.62]; p=0.003), Figure 4.

Associations between other prognostic factors and time to event outcomes were as expected; MRD positive patients had significantly worse EFS and OS and were at higher risk of relapse and non-relapse mortality. Patients given RIC had a significantly inferior EFS, while we saw that patients with fully matched cords were at lower risk of non-relapse mortality. Older patients in the cohort were at significantly higher risk of developing chronic GVHD.

Owing to the discrepancy in proportion of MRD positive patients between the TRCB and comparator groups, patients were stratified by flow MRD status for a further univariable analysis. In patients who were flow MRD positive going into transplant, TRCB recipients had significantly superior EFS compared with recipients of other transplants, 50% (95% CI: 34%-64%) vs 21% (12%-32%) (HR 0.55 [95% CI: 0.34-0.90]; p= 0.017), Figure 5A. EFS was similar between the 2 cohorts for patients who were MRD negative at transplant by univariable analysis, 79% (64%-88%) for the TRCB group and 71% (64%-78%) for the comparators (HR 0.86 [95%CI: 0.45-1.65]; p= 0.649), Figure 5B (p-value for interaction p=0.29).

cGFRFS was significantly improved for MRD positive recipients of a T-replete cord compared with other transplant type, 48% (95% CI: 32%-62%) vs 11% (5%-21%) (p= 0.001, HR 0.44 [95% CI 0.28,0.71]), figure 6A. In MRD negative patients, cGFRFS was 67% and 56% for TRCB and comparator transplant recipients respectively, (p= 0.30, HR 0.75 [95% CI: 0.43, 1.3]), Figure 6B (p-value for interaction p=0.22).

The 2-year cumulative incidence of relapse was 23.2% (95% CI 15.8-33.3) for the entire TRCB cohort versus 32.5% (95% CI 27-38.9) for comparator group, and again was not significantly different (HR 0.71 [95% CI 0.44-1.14]; p=0.16). When this was stratified by flow MRD status, a striking reduction in relapse was seen for flow MRD positive patients in the TRCB setting, where the risk of relapse was 36.2% compared with 66.2% for other donors, (p= 0.007, HR 0.46 [95%CI:0.26,0.80]), Figure 7A. In MRD negative patients, a similar trend was seen with relapse rates of 9.9% and 27% in the TRCB and comparator groups respectively (p= 0.049, HR 0.36 [95% CI:0.13- 0.94]), Figure 7B (p-value for interaction: p=0.67).

MVA were performed for EFS, OS and relapse (Table 2). Once adjusted for other important baseline factors, EFS and relapse showed a significant benefit for TRCB transplants; EFS HR 0.57 [95%0.35-0.91]; p=0.019 and relapse: HR: 0.46 [95%CI: 0.26-0.81], p=0.008. This change in the treatment group effect appears to be driven by the excess of MRD positives within the T-replete cohort, with the HR for EFS changing from 0.76 (univariable, complete cases) to 0.54 when adjusted for MRD alone. Although not quite significant, there was also some evidence for an improvement in OS; HR 0.65 [95 % CI 0.39-1.07]; p=0.088. MRD remained significant in all analyses, with MDS patients having a significantly better OS than AML. There was a significant interaction between age and treatment group for relapse (interaction p=0.02); TRCB transplants appeared to be beneficial for all, but the effect may have been larger in older patients.

The number of events precluded full MVA for treatment-related mortality (33 events) and chronic GVHD (48 events), instead forwards selection was performed to add in any variable significant ($p<0.05$) to a model containing the treatment group (Table 2). The interactions with each variable were also explored. For TRM no other variables were significant in forwards selection, though there was some evidence that the effect was greater for HLA mismatched cords; HR 3.12 [95% CI: 0.89-10.86] vs HR 0.43 [95% CI: 0.06-3.25], interaction p=0.102. Causes of death were not available for the comparator group, but within the T-replete cohort the most common cause of TRM was infection (n=7), followed by GVHD (n=5). The remaining three deaths were due to multiple organ failure secondary to underlying transplant-related microangiopathy (TMA).

Age was the only additional factor associated with cGVHD with older patients at higher risk. The effect of treatment group remained very similar: HR=0.28 [95% CI:0.11-0.70]; p-value=0.007.

To account for the difference in follow-up, a sensitivity analysis was performed which censored all patients at 24.6 months (i.e. median follow-up for the TRCB group) , these results were very similar MVA EFS (14 censored events, HR: 0.58[0.35-0.93], p=0.025), time to relapse (4 censored events, HR: 0.48[0.27-0.87), p=0.015) and OS (14 censored events, HR: 0.75[0.44-1.26], p = 0.280). All cGVHD events occurred before 2 years.

Discussion

In this large multicentre series of TRCB transplant in very high-risk paediatric myeloid malignancy, we demonstrate excellent outcomes, even in refractory disease, and markedly superior to transplant using other cell sources. Although the TRCB transplant group had higher rates of MRD positivity, refractory disease and 2nd transplant, multivariable analysis showed both strikingly higher EFS and reduced RR, with a trend towards higher OS in the TRCB cohort than the comparator group, a contemporary cohort of transplants from other stem cell sources. This impact of TCRB was present at all levels of residual disease.

We recognise that there are limitations to our study; particularly that the groups were not randomly assigned, and that the follow up of the TRCB cohort is shorter than the comparator. These imbalances, however, favoured the comparator group (lower risk patients) with MVA allowing us to adjust for these for known confounders, and a sensitivity analysis showed that results held during the first 2 years, suggesting that, although we cannot completely rule out a different pattern of events in the TRCB group, any later comparator events were not having an undue influence. The marked beneficial effect of TRCB in reducing relapse and promoting GVHD-free, DFS mandates a randomised clinical trial of cell source in children with myeloid malignancy requiring transplant to confirm these results. This is particularly true, given the decline in the use of CB as a cell source for transplant.

Early recognition of those with refractory disease will enable early transplant with TCRB, saving continued exposure to chemotherapy, including anthracyclines, with significant late effects. Although acute GVHD is significant after CB SCT, chronic GVHD is much reduced compared to other cell sources, even where the HLA mismatch is greater (15, 16). The

composite endpoint of GFRFS, which is the most clinically relevant outcome measure to assess in this setting, is much reduced in T-replete cord blood transplant compared to other cell sources in those with residual disease before transplant (15, 16). In those with residual disease, transplant with other cell sources may provide a cure, but this is often associated with chronic GVHD, including after donor lymphocyte infusion in those with detectable disease after transplant.

Our findings significantly extend those of Milano *et al* (20) which were from a single institution, and adult patients with both AML/MDS and ALL, and reported improved DFS only in those with measurable disease at the time of transplant. Similarly, Shimomura *et al* (21) reported a lower risk of relapse associated with CB SCT in a more limited study, comparing CB to matched family donors only, and studying only adult patients with AML not in remission. Our data are derived from a multi-centre paediatric study of patients only with AML/MDS and demonstrating superior outcomes of TRCB transplant at all levels of MRD.

The role of pre-transplant MRD in determining transplant outcome is a challenging issue with limited prospective studies (25, 26). We used multi-parameter flow cytometry MRD assessment with a threshold of 0.1% in our study to reflect the methodology used in the UK paediatric AML and MDS national treatment protocol (27). The prognostic impact of flow MRD in our data is in keeping with the recent prospective FIGARO study in adult AML which demonstrated a higher rate of relapse for patients who had a flow-determined MRD of 0.2% or above pre-transplant (28). The marked reduction in relapse for TRCB recipients in our analysis suggests that this may be the most appropriate form of transplant for patients with MRD positive disease, however, we acknowledge that prospective studies are needed to confirm this.

The higher TRM associated with cord blood transplantation (29) is perceived as a barrier, particularly in the era of increasing haploidentical SCT (30). There is little doubt that other transplants, involving higher stem cell doses and graft T cell depletion, are more straightforward, but the superior EFS for T-replete cord recipients, particularly those with positive MRD, shows that the loss of a GVL effect associated with such strategies is disadvantageous for these patients. The higher TRM in the cord setting arises due to a combination of high rates of acute GVHD, increased graft failure, immune cytopenia and respiratory failure (31).

Reduction of cord blood transplant TRM will accentuate the superiority of CB transplant, and likely will require collaborative working in several areas, including assistance in graft selection, optimising GVHD prophylaxis and management, and reduction of viral infection including with newer agents (32, 33, 34, 35). Cord stem cell expansion technology has been investigated in several clinical trials and improves outcomes since it allows consideration of better matched units previously not selected because of an inferior cell dose, accelerates neutrophil and platelet recovery, reduces bacterial and fungal infection, and reduces time in hospital.

Several studies have highlighted the low relapse rate for cord blood transplantation (21, 36), and compared to other donor sources (29) and our data replicates these findings. The important role of T-cells in enhancing the GVL effect in CB transplant has been

demonstrated by data from Zheng et al (37), where patients receiving serotherapy had significantly higher relapse rates and inferior leukaemia-free survival compared to those receiving a T-replete transplant. The significance of cord T-cells in reducing relapse may also explain the findings of a recent EBMT-Eurocord acute leukaemia study that failed to demonstrate a reduced relapse rate for cord compared to haploidentical SCT since most cord recipients also received T-cell depleting serotherapy (38). Xenograft models have shown that cord blood T-cells exhibit a superior anti-leukaemia effect compared to adult T-cells (22) suggesting that cord blood T-cells have an ontogeny difference that may be implicated in the superior GVL effect observed with CB SCT.

The relapse rate for cord recipients in our cohort, although lower than recipients of other transplants, was higher than those in some previous retrospective adult studies (12, 21). The patient cohorts were different in these studies and most transplants used double-unit cord blood transplants whilst most patients in ours received single-unit cord blood transplants (95%). The RR has been shown in randomised studies to be reduced in double cord compared to single cord transplants(39). Although greater HLA disparity in CB transplants has been correlated with reduced RR, we didn't show a difference in relapse between fully matched and mismatched cord recipients in our cohort (18, 19, 29, 40).

Our findings suggest that CB might be considered the optimal donor cell source in children requiring transplant for AML as MVA demonstrates significantly improved DFS and RR in all patients. This should be confirmed in a prospective trial comparing RR and EFS in CB and other HSCT in high-risk AML/MDS, including MRD positive and refractory disease.

Author's contributions

RFW and PA conceived and designed study. RFW, PA, KR, OM-D, CF, BJ, KP, SL, BG, WR, PE approved the study through the UK Paediatric BMT cooperative network. KM, AR, KP, NB, OM-D, OO'C, CF, AD, VB, PE, BG, WR, SA, JJ, RD, PV collected and supplied all institutional data. CH and RFW wrote the manuscript. CH, SG and AK analysed data. SG and AK critically interpreted data and produced figures and tables. All authors reviewed, edited and approved the submitted manuscript.

Conflict of interest

None of the authors have any conflict of interest related to this study.

Funding source

None

Ethics committee approval

All patients consented at time of transplant for use of transplant data in research

References

1. Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, et al. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020;34(2):613-24.
2. Vyas P, Appelbaum FR, Craddock C. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2015;21(1):8-15.
3. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-77.
4. Quarello P, Fagioli F, Basso G, Putti MC, Berger M, Luciani M, et al. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial. Br J Haematol. 2015;171(4):566-73.
5. Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol. 2008;26(26):4326-32.
6. Skalska-Sadowska J, Wachowiak J, Polish Pediatric Leukemia/Lymphoma Study G, Skalska-Sadowska J, Wachowiak J, Zajac-Spychala O, et al. Outcome of refractory and relapsed acute myeloid leukemia in children treated during 2005-2011 - experience of the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG). Contemp Oncol (Pozn). 2014;18(1):48-53.
7. Uden T, Bertaina A, Abrahamsson J, Ansari M, Balduzzi A, Bourquin JP, et al. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children. Br J Haematol. 2020;189(4):745-50.
8. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010;55(3):421-9.
9. Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, et al. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2019;25(2):301-6.
10. Zilberberg J, Feinman R, Korngold R. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21(6):1000-7.
11. Sweeney C, Vyas P. The Graft-Versus-Leukemia Effect in AML. Front Oncol. 2019;9:1217.
12. Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-Blood Transplantation in Patients with Minimal Residual Disease. N Engl J Med. 2016;375(10):944-53.
13. Shimomura Y, Sobue T, Hirabayashi S, Kondo T, Mizuno S, Kanda J, et al. Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia. 2022;36(4):1132-8.
14. Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, et al. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord

blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplant. 2016;51(12):1588-93.
15. Keating AK, Langenhorst J, Wagner JE, Page KM, Veys P, Wynn RF, et al. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. Blood Adv. 2019;3(7):1118-28.
16. Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, et al. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020;4(10):2227-35.
17. Chiesa R, Gilmour K, Qasim W, Adams S, Worth AJ, Zhan H, et al. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol. 2012;156(5):656-66.
18. Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, et al. Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. Biol Blood Marrow Transplant. 2020;26(3):519-28.
19. Sanz J, Jaramillo FJ, Planelles D, Montesinos P, Lorenzo I, Moscardo F, et al. Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2014;20(1):106-10.
20. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339-48.
21. Barker JN, Devlin SM, Naputo KA, Skinner K, Maloy MA, Flynn L, et al. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. Blood Adv. 2020;4(23):6064-76.
22. Hiwarkar P, Qasim W, Ricciardelli I, Gilmour K, Quezada S, Saudemont A, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015;126(26):2882-91.
23. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
24. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401 e1.
25. Loke J, Buka R, Craddock C. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? Front Immunol. 2021;12:659595.
26. Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129-46.
27. Myechild 01 International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia. 2018.
28. Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2021;39(7):768-78.

29. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947-54.
30. Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56(7):1651-64.
31. Wynn R, Nataraj R, Nadaf R, Poulton K, Logan A. Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications. Front Cell Dev Biol. 2022;10:836594.
32. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. New England Journal of Medicine. 2017;377(25):2433-44.
33. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Journal of Clinical Oncology. 2021;39(17):1865-77.
34. Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2020;7(2):e134-e45.
35. Horwitz ME, Stiff PJ, Cutler C, Brunstein C, Hanna R, Maziarz RT, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429-40.
36. Barker JN, Fei M, Karanes C, Horwitz M, Devine S, Kindwall-Keller TL, et al. Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. Br J Haematol. 2015;168(3):405-12.
37. Zheng C, Luan Z, Fang J, Sun X, Chen J, Li CK, et al. Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies. Biol Blood Marrow Transplant. 2015;21(4):707-12.
38. Giannotti F, Labopin M, Shouval R, Sanz J, Arcese W, Angelucci E, et al. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. J Hematol Oncol. 2018;11(1):110.
39. Michel G, Galambrun C, Sirvent A, Pochon C, Bruno B, Jubert C, et al. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood. 2016;127(26):3450-7.
40. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123(1):133-40.

Figure legends

Figure 1: **T-replete cord EFS stratified by MRD.** Patients who were MRD negative at transplant have significantly improved EFS compared with MRD positive patients, 2-year EFS 79% (95% CI: 64%- 88%) versus 50% (34%-64%), (HR 2.58 [95% CI: 1.27-5.26]; p = 0.009).

Figure 2: T-replete cord EFS stratified by clinical disease status. 2-year EFS was 79.6% for those in CR2, 67% for high risk CR1, 60.9% for those with primary refractory disease and 46.5% for those with relapsed refractory disease.

Figure 3: T-replete cord versus comparator cohort NRM. T-replete cord blood was associated with significantly higher non-relapse mortality (HR 2.05 [95% CI 1.05-4.01]; p=0.04) by univariable analysis with 2-year cumulative incidence of 12.3% (95% CI 7.3-20.4) for the T-replete cord cohort versus 7.2% (4.6-11.2) for the comparator group.

Figure 4: T-replete cord vs comparator cohort incidence of chronic GvHD. Univariable analysis shows a significantly lower risk of developing chronic GvHD for T-replete cord recipients compared to patients in the comparator group (HR 0.25 [95% CI 0.10-0.62]; p= 0.003), with a cumulative incidence of 5% (95% CI 0.02-0.11) for the T-replete cord patients compared with 19.4% (0.15-0.25) for the comparator.

Figure 5: T-replete cord vs comparator cohort EFS. (5A) In patients who were flow MRD positive going into transplant, T-replete cord blood recipients had significantly better EFS compared with recipients of other transplants, 2-year EFS 50% (95% CI: 34%-64%) vs 21% (12%-32%) (HR 0.55 [95% CI:0.34-0.90]; p= 0.017). (5B) For patients who were MRD negative at transplant, there was no significant difference in EFS between patients in the T-replete cord vs comparator group, 2-year EFS was 79% (64%-88%) for T-replete cord recipients and 71% (64%-78%) for the comparator group (HR 0.86 [95% CI: 0.45-1.65]; p= 0.649).

Figure 6: T-replete cord vs comparator cohort cGFRFS. (6A) cGFRFS was significantly improved for MRD positive recipients of a T-replete cord compared with other transplant type, 48% (95% CI: 32%-62%) vs 11% (5%-21%) (HR 0.44 [95% CI 0.28-0.71]; p= 0.001). (6B) In MRD negative patients, cGFRFS was 67% (51%-79%) and 56% (48%-64%) for TRCB and comparator transplant recipients respectively, (HR 0.75 [95% CI: 0.43, 1.3]; p= 0.30), p-value for interaction = 0.17.

Figure 7: T-replete cord vs comparator relapse risk. (7A) The 2-year cumulative incidence of relapse for flow MRD positive patients was 66.2% for T-replete cord recipients compared with 36.2% for other donors (HR 0.46 [95% CI: 0.26, 0.80]; p= 0.007). (7B) In MRD negative patients a similar trend was seen with 2-year cumulative incidence of relapse of 8.9% for T-replete cord patients and 23.3% for the comparator group (HR 0.36 [95% CI: 0.13-0.94]; p=0.049), p-value for interaction: p=0.67.

Table 1: Patient and Transplant Characteristics

Cord paper tables

Table 1 Patient and transplant characteristics

	T-replete cord (n=112)	Comparator (n=255)	p-value*
Age, years	6.5 years (2.5-11)	8.9 years (3.9-13.2)	0.005
Diagnosis			
AML	102 (91.1%)	232 (91%)	
MDS	10 (9%)	23 (9%)	0.978
Conditioning			
MAC	92 (82.1%)	233 (91.4%)	
RIC	20 (17.9%)	22 (8.6%)	0.011
HLA-match			
Fully matched (8/8 cord or 10/10 MUD or sib)	32 (28.6%)	208 (81.6%)	
Mismatched (≤7/8 or ≤9/10)	80 (71.4%)	47 (18.4%)	<0.001
MRD			
Positive	57 (51.4%)	60 (26.1%)	
Negative	54 (48.7%)	170 (73.9%)	
No marker	0	25	<0.001[ii]
Clinical disease status			
Primary refractory	29 (25.9%)	13 (5.1%)	
Relapsed Refractory	23 (20.5%)	9 (3.5%)	
CR2	22 (19.6%)	84 (32.9%)	
High Risk CR1	38 (33.9%)	118 (46.3%)	
Other (untreated MDS)	0	31 (12.2%)	<0.001[iii]
Previous BMT	24 (21.4%)	13 (5.1%)	<0.001

Data are median (IQR; range), median (IQR), or n (%). *Wilcoxon rank-sum test (continuous), Pearson Chi-square test or Fisher's exact test (discrete variables). Category "Other" of clinical disease status and category "No marker" of MRD were not included in the calculation of p-value.

Table 2 Multivariable cox regressions

*models chosen with forward selection

	EFS		OS		Relapse		TRM*		cGvHD*	
	HR(95% CI)	**p-value**	**HR(95% CI)**	**p-value**	**HR(95% CI)**	**p-value**	**HR(95% CI)**	**p-value**	**HR(95% CI)**	**p-value**
T-replete VS Comparator	0.57(0.35-0.91)	0.019	0.65(0.39-1.07)	0.088	0.46(0.26-0.81)	0.008	2.04(1.03-4.06)	0.042	0.28(0.11-0.70)	0.007
RIC VS MAC	1.52()0.93-2.48	0.096	1.41(0.82-2.41)	0.211	1.40(0.80-2.47)	0.241	-	-	-	-
MRD Positive VS Negative	3.97(2.74-5.75)	<0.001	4.46-2.98-6.68)	<0.001	4.09(2.68-6.25)	<0.001	-	-	-	-
Age at transplant (per 5y)	0.99(0.83-1.18)	0.902	0.93(0.77-1.31)	0.483	0.90(0.74-1.10)	0.313	-	-	1.35(1.01-1.81)	0.039
MDS VS AML	0.79(0.45-1.41)	0.428	0.47(0.23-0.97)	0.040	0.96(0.51-1.83)	0.908	-	-	-	-
Previous BMT VS No previous BMT	1.36(0.76-2.40)	0.298	1.36(0.73-2.52)	0.329	1.10(0.55-2.17)	0.790	-	-	-	-
Fully Matched VS Mismatched cord	0.99(0.66-1.50)	0.976	0.86(0.55-1.33)	0.488	1.34(0.81-2.22)	0.251	-	-	-	-

EFS: Event Free Survival, OS: Overall Survival, TRM: Transplant Related Mortality, cGvHD: Chronic Graft versus host disease, RIC: Reduced-Intensity Conditioning, MAC: Myeloablative Conditioning, MRD: Minimal Residual Disease, MDS: myelodysplastic syndrome, AML: acute myeloid leukaemia, BMT: Bone Marrow Transplant

Figure 1



Figure 1: **T-replete cord EFS stratified by MRD.** Patients who were MRD negative at transplant have significantly improved EFS compared with MRD positive patients, 2-year EFS 79% (95% CI: 64%- 88%) versus 50% (34%-64%), (HR 2.58 [95% CI: 1.27-5.26]; p = 0.009)

Figure 2



Number at risk

CR1	38	24	14	11	10	7	7	3	1	0
CR2	22	13	12	8	6	5	2	0	0	0
Primary refractory	29	13	8	7	4	4	2	1	1	1
Relapsed refractory	23	9	4	4	3	1	0	0	0	0

Figure 3



Figure 3: T-replete cord versus comparator cohort NRM. T-replete cord blood was associated with significantly higher non-relapse mortality (HR 2.05 [95% CI 1.05-4.01]; p=0.04) by univariable analysis with 2-year cumulative incidence of 12.3% (95% CI 7.3-20.4) for the T-replete cord cohort versus 7.2% (4.6-11.2) for the comparator group.

Figure 4



Figure 4: T-replete cord vs comparator cohort incidence of chronic GvHD. Univariable analysis shows a significantly lower risk of developing chronic GvHD for T-replete cord recipients compared to patients in the comparator group (HR 0.25 [95% CI 0.10-0.62]; p= 0.003), with a cumulative incidence of 5% (95% CI 0.02-0.11) for the T-replete cord patients compared with 19.4% (0.15-0.25) for the comparator.

Figure 5

5A



Number at risk										
Comparator	60	27	17	11	10	10	8	7	3	0
T-replete cord blood	57	24	16	15	10	5	2	1	1	1

5B



Number at risk										
Comparator	170	131	105	88	71	57	40	23	8	2
T-replete cord blood	54	35	22	15	13	12	9	3	1	0

Figure 5: T-replete cord vs comparator cohort EFS. (5A) In patients who were flow MRD positive going into transplant, T-replete cord blood recipients had significantly better EFS compared with recipients of other transplants, 2-year EFS 50% (95% CI: 34%-64%) vs 21% (12%-32%) (HR 0.55 [95% CI:0.34-0.90]; p= 0.017). (5B) For patients who were MRD negative at transplant, there was no significant difference in EFS between patients in the T-replete cord vs comparator group, 2-year EFS was 79% (64%-88%) for T-replete cord recipients and 71% (64%-78%) for the comparator group (HR 0.86 [95% CI: 0.45-1.65]; p= 0.649).

Figure 6



Figure 6: T-replete cord vs comparator cohort cGFRFS. (6A) cGFRFS was significantly improved for MRD positive recipients of a T-replete cord compared with other transplant type, 48% (95% CI: 32%-62%) vs 11% (5%-21%) (HR 0.44 [95% CI 0.28-0.71]; p= 0.001). (6B) In MRD negative patients, cGFRFS was 67% (51%-79%) and 56% (48%-64%) for TRCB and comparator transplant recipients respectively, (HR 0.75 [95% CI: 0.43, 1.3]; p= 0.30), p-value for interaction = 0.22.

Figure 7

7A



7B



Figure 7: T-replete cord vs comparator relapse risk. (7A) The 2-year cumulative incidence of relapse for flow MRD positive patients was 36.2% for T-replete cord recipients compared with 66.2% for other donors (HR 0.46 [95% CI: 0.26, 0.80]; p= 0.007). (7B) In MRD negative patients a similar trend was seen with 2-year cumulative incidence of relapse of 8.9% for T-replete cord patients and 23.3% for the comparator group (HR 0.36 [95% CI: 0.13-0.94]; p=0.049). p-value for interaction: p=0.67